432 related articles for article (PubMed ID: 15674947)
1. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Cheng J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
[TBL] [Abstract][Full Text] [Related]
2. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J
Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356
[TBL] [Abstract][Full Text] [Related]
5. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD004434. PubMed ID: 23450552
[TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
7. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
[TBL] [Abstract][Full Text] [Related]
9. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
[TBL] [Abstract][Full Text] [Related]
10. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Steiner MK; Preston IR
Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
[TBL] [Abstract][Full Text] [Related]
11. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
Fine N; Dias B; Shoemaker G; Mehta S
Can J Cardiol; 2009 Mar; 25(3):e63-8. PubMed ID: 19279988
[TBL] [Abstract][Full Text] [Related]
15. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J
Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350
[TBL] [Abstract][Full Text] [Related]
17. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Cacoub P; Amoura Z; Langleben D
Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
[TBL] [Abstract][Full Text] [Related]
19. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
Gabler NB; French B; Strom BL; Liu Z; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
Chest; 2012 Jan; 141(1):20-26. PubMed ID: 21940766
[TBL] [Abstract][Full Text] [Related]
20. Sitaxsentan for treatment of pulmonary hypertension.
Wittbrodt ET; Abubakar A
Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
